Nonfunctioning pituitary macroadenomas: Diagnosis, treatment and follow-up;Niet-functionerende macroadenomen van de hypofyse: Diagnostiek, behandeling en follow-up

Nederlands Tijdschrift voor Geneeskunde

Volumn 152, Issue 14, 2008, Pages 792-796

  Dekkers, O M ^a   Neelis, K J ^a   De Keizer, R J W ^a   Voormolen, J H C ^a   Pereira, A M ^a   Romijn, J A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE;

CLINICAL FEATURE; FOLLOW UP; HEADACHE; HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS ADENOMA; REVIEW; TREATMENT PLANNING; VISUAL IMPAIRMENT;

ADENOMA; FOLLOW-UP STUDIES; HEADACHE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PITUITARY NEOPLASMS; PROGNOSIS; QUALITY OF LIFE;

EID: 42149187686     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Asa SL, Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev. 1998;19:798-827.
2. Ironside JW. Best practice no 172: pituitary gland pathology. J Clin Pathol. 2003;56:561-8.
3. Burrow GN, Wortzman G, Rewcastle NB, Holgate RC, Kovacs K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med. 1981;304:156-8.
4. Molitch ME. Pituitary incidentalomas. Endocrinol Metab Clin North Am. 1997;26:725-40.
5. Davis JR, Farrell WE, Clayton RN. Pituitary tumours. Reproduction. 2001;121:363-71.
6. Asa SL, Gerrie BM, Singer W, Horvath E, Kovacs K, Smyth HS. Gonadotropin secretion in vitro by human pituitary null cell adenomas and oncocytomas. J Clin Endocrinol Metab. 1986;62:1011-9.
7. Nammour GM, Ybarra J, Naheedy MH, Romeo JH, Aron DC. Incidental pituitary macroadenoma: a population-based study. Am J Med Sci. 1997;314:287-91.
8. Nobels FR, Kwekkeboom DJ, Herder WW de, Lamberts SW. Klinisch niet-functionerende hypofyseadenomen; diagnostische mogelijkheden en therapeutische opties. Ned Tijdschr Geneeskd. 1992;136:1148-52.
9. Dekkers OM, Pereira AM, Roelfsema F, Voormolen JH, Neelis KJ, Schroijen MA, et al. Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab. 2006;91:1796-801.
10. Cardoso ER, Peterson EW. Pituitary apoplexy: a review. Neurosurgery. 1984;14:363-73.
11. St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxf). 1996;44:305-9.
12. Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N, et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol (Oxf). 2006;65:524-9.
13. Freda PU, Wardlaw SL, Post KD. Unusual causes of sellar/parasellar masses in a large transsphenoidal surgical series. J Clin Endocrinol Metab. 1996;81:3455-9.
14. Fainstein Day P, Guitelman M, Artese R, Fiszledjer L, Chervin A, Vitale NM, et al. Retrospective multicentric study of pituitary incidentalomas. Pituitary. 2004;7:145-8.
15. Feldkamp J, Santen R, Harms E, Aulich A, Modder U, Scherbaum WA. Incidentally discovered pituitary lesions: high frequency of macroadenomas and hormone-secreting adenomas - results of a prospective study. Clin Endocrinol (Oxf). 1999;51:109-13.
16. Sanno N, Oyama K, Tahara S, Teramoto A, Kato Y. A survey of pituitary incidentaloma in Japan. Eur J Endocrinol. 2003;149:123-7.
17. Dekkers OM, Hammer S, Keizer RJ de, Roelfsema F, Schutte PJ, Smit JW, et al. The natural course of non-functioning pituitary macroadenomas. Eur J Endocrinol. 2007;156:217-24.
18. Arita K, Tominaga A, Sugiyama K, Eguchi K, Iida K, Sumida M, et al. Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination. J Neurosurg. 2006;104:884-91.
19. Wichers-Rother M, Hoven S, Kristof RA, Bliesener N, Stoffel-Wagner B. Non-functioning pituitary adenomas: endocrinological and clinical outcome after transsphenoidal and transcranial surgery. Exp Clin Endocrinol Diabetes. 2004;112:323-7.
20. Comtois R, Beauregard H, Somma M, Serri O, Aris-Jilwan N, Hardy J. The clinical and endocrine outcome to trans-sphenoidal microsurgery of nonsecreting pituitary adenomas. Cancer. 1991;68:860-6.
21. Soto-Ares G, Cortet-Rudelli C, Assaker R, Boulinguez A, Dubest C, Dewailly D, et al. MRI protocol technique in the optimal therapeutic strategy of non-functioning pituitary adenomas. Eur J Endocrinol. 2002;146:179-86.
22. Arafah BM. Reversible hypopituitarism in patients with large non-functioning pituitary adenomas. J Clin Endocrinol Metab. 1986;62:1173-9.
23. Selman WR, Laws jr ER, Scheithauer BW, Carpenter SM. The occurrence of dural invasion in pituitary adenomas. J Neurosurg. 1986;64:402-7.
24. Park P, Chandler WF, Barkan AL, Orrego JJ, Cowan JA, Griffith KA, et al. The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery. 2004;55:100-6.
25. Bergh AC van den, Berg G van den, Schoorl MA, Sluiter WJ, Vliet AM van der, Hoving EW, et al. Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy. Int J Radiat Oncol Biol Phys. 2007;67:863-9.
26. Ebersold MJ, Quast LM, Laws jr ER, Scheithauer B, Randall RV. Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas. J Neurosurg. 1986;64:713-9.
27. Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML. Hypopituitarism following external radiotherapy for pituitary tumours in adults. Q J Med. 1989;70:145-60.
28. Nelson PB, Goodman ML, Flickenger JC, Richardson DW, Robinson AG. Endocrine function in patients with large pituitary tumors treated with operative decompression and radiation therapy. Neurosurgery. 1989;24:398-400.
29. Tsang RW, Brierley JD, Panzarella T, Gospodarowicz MK, Sutcliffe SB, Simpson WJ. Radiation therapy for pituitary adenoma: treatment outcome and prognostic factors. Int J Radiat Oncol Biol Phys. 1994;30:557-65.
30. Breen P, Flickinger JC, Kondziolka D, Martinez AJ. Radiotherapy for nonfunctional pituitary adenoma: analysis of long-term tumor control. J Neurosurg. 1998;89:933-8.
31. Minniti G, Traish D, Ashley S, Gonsalves A, Brada M. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab. 2005;90:800-4.
32. Brada M, Ajithkumar TV, Minniti G. Radiosurgery for pituitary adenomas. Clin Endocrinol (Oxf). 2004;61:531-43.
33. Muacevic A, Uhl E, Wowra B. Gamma knife radiosurgery for nonfunctioning pituitary adenomas. Acta Neurochir Suppl. 2004;91:51-4.
34. Sheehan JP, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery for residual or recurrent nonfunctioning pituitary adenoma. J Neurosurg. 2002;97:408-14.
35. Sheehan JP, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery for nonfunctioning pituitary adenoma. Neurosurg Focus. 2003;14:e9.
36. Sheehan JP, Niranjan A, Sheehan JM, Jane jr JA, Laws ER, Kondziolka D, et al. Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg. 2005;102:678-91.
37. Grossman A, Ross R, Charlesworth M, Adams CB, Wass JA, Doniach I, et al. The effect of dopamine agonist therapy on large functionless pituitary tumours. Clin Endocrinol (Oxf). 1985;22:679-86.
38. Bevan JS, Burke CW. Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine. Clin Endocrinol (Oxf). 1986;25:561-72.
39. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 1992;13:220-40.
40. Colao A, Lombardi G, Annunziato L. Cabergoline. Expert Opin Pharmacother. 2000;1:555-74.
41. Pivonello R, Matrone C, Filippella M, Cavallo LM, di Somma C, Cappabianca P, et al. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab. 2004;89:1674-83.
42. Greenman Y, Tordjman K, Osher E, Veshchev I, Shenkerman G, Reider-Groswasser II, et al. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin Endocrinol (Oxf). 2005;63:39-44.
43. Gittoes NJ, Bates AS, Tse W, Bullivant B, Sheppard MC, Clayton RN, et al. Radiotherapy for non-function pituitary tumours. Clin Endocrinol (Oxf). 1998;48:331-7.
44. Greenman Y, Ouaknine G, Veshchev I, Reider-Groswasser II, Segev Y, Stern N. Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and re-growth. Clin Endocrinol (Oxf). 2003;58:763-9.
45. Dekkers OM, Klaauw AA van der, Pereira AM, Biermasz NR, Honkoop PJ, Roelfsema F, et al. Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab. 2006;91:3364-9.
46. Aken MO van, Pereira AM, Biermasz NR, Thiel SW van, Hoftijzer HC, Smit JW, et al. Quality of life in patients after long-term biochemical cure of Cushing's disease. J Clin Endocrinol Metab. 2005;90:3279-86.
47. Romijn JA, Smit JW, Lamberts SW. Intrinsic imperfections of endocrine replacement therapy. Eur J Endocrinol. 2003;149:91-7.